Literature DB >> 1370413

Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus.

A Apolloni1, D Moss, R Stumm, S Burrows, A Suhrbier, I Misko, C Schmidt, T Sculley.   

Abstract

Previous results have identified two distinct cytotoxic T lymphocyte (CTL) epitopes encoded by Epstein-Barr virus (EBV), TETA (ORF BLRF3/BERF1 residues 329-353) and EENL (ORF BERF3/BERF4 residues 290-309). Measurement of the specificities of CTL clones (TETA-specific clone 13 and EENL-specific clone 7) directed against these epitopes indicated that the EENL epitope is conserved in all strains of EBV tested while the TETA epitope varied between individual virus strains. Sequencing of the DNA regions encoding these two CTL epitopes in different EBV isolates confirmed these interpretations and demonstrated that different TETA epitope sequences were encoded by B-type EBV strains and by the B95-8 isolate of EBV compared to the other A-type EBV strains. Titration of synthetic variants of the TETA epitope revealed that the epitope encoded by B95-8 was 15-fold less efficient as a T cell epitope than the sequence encoded by other A-type viral strains while the TETA variant encoded by the B-type strains displayed essentially no activity as a T cell epitope.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370413     DOI: 10.1002/eji.1830220127

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan.

Authors:  M Tanaka; Y Kawaguchi; J Yokofujita; M Takagi; Y Eishi; K Hirai
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

2.  Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes.

Authors:  J T Voeten; T M Bestebroer; N J Nieuwkoop; R A Fouchier; A D Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 3.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

4.  Epstein-Barr virus isolates retain their capacity to evade T cell immunity through BNLF2a despite extensive sequence variation.

Authors:  Daniëlle Horst; Scott R Burrows; Derek Gatherer; Bonnie van Wilgenburg; Melissa J Bell; Ingrid G J Boer; Maaike E Ressing; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 5.  Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.

Authors:  D J Moss; I S Misko; T B Sculley; A Apolloni; R Khanna; S R Burrows
Journal:  Springer Semin Immunopathol       Date:  1991

6.  Prediction of an HLA B8-restricted influenza epitope by motif.

Authors:  A Suhrbier; C Schmidt; A Fernan
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

7.  Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells.

Authors:  I V Redchenko; A B Rickinson
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Authors:  J M Brooks; D S Croom-Carter; A M Leese; R J Tierney; G Habeshaw; A B Rickinson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

9.  T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.

Authors:  Q Chen; M Smith; T Nguyen; D W Maher; P Hersey
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

10.  A mutation in the HLA-B*2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro.

Authors:  E G M Berkhoff; A C M Boon; N J Nieuwkoop; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.